Vasopressin Patent Expiration
Vasopressin is Used for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. It was first introduced by Ph Health Ltd
Vasopressin Patents
Given below is the list of patents protecting Vasopressin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vasopressin In Sodium Chloride 0.9% | US12447190 | Sep 27, 2044 | Baxter Hlthcare Corp | |
| Vasostrict | US10010575 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US12186362 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9375478 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9687526 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9744209 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9744239 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9750785 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9919026 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9925233 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9925234 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9937223 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9962422 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9968649 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9974827 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
| Vasostrict | US9981006 | Vasopressin formulations for use in treatment of hypotension | Jan 30, 2035 | Ph Health |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Vasopressin's patents.
Latest Legal Activities on Vasopressin's Patents
Given below is the list recent legal activities going on the following patents of Vasopressin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Dec, 2025 | US10010575 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Oct, 2025 | US9968649 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Oct, 2025 | US9962422 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Oct, 2025 | US9981006 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Oct, 2025 | US9974827 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Sep, 2025 | US9937223 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Aug, 2025 | US9925233 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Aug, 2025 | US9925234 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Aug, 2025 | US9919026 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2025 | US9750785 |
Vasopressin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vasopressin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Dose-finding Study of JMKX003142 in Treatment of Renal Edema | Jemincare | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1 |
| Intranasal Vasopressin Treatment in Children With Autism | Stanford University | NA |
COMPLETED
(May 1, 2026)
| PHASE2, PHASE3 |